Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
91 ngày trước
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
125 ngày trước
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
272 ngày trước
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
853 ngày trước
Canadian Market Headed For Weak Close
Disappointing earnings updates from U.S. tech majors Microsoft Inc., and Meta Platforms, anxiety ahead of U.S. presidential election and the Federal Reserve's monetary policy meeting, and weak commodity prices are weighing on the Canadian market.
RTTNews
|
4h 35phút trước
Swiss Market Ends Weak Again
For the second consecutive day, the Switzerland market languished in red right through the day's session, as weak earnings updates from U.S. technology majors Microsoft Inc., and Meta Platforms, and weak euro zone inflation data hurt sentiment and sent stock prices drifting down south on Thursday.
RTTNews
|
5h 25phút trước
Pound Falls After Autumn Statement
The pound weakened against its major counterparts in the New York session on Thursday, following the announcement of the nation's latest budget, which included tax rises and big spending plans.
RTTNews
|
5h 26phút trước
European Stocks Close Notably Lower On Weak Earnings, Economic Data
European stocks closed notably lower on Thursday as disappointing earnings updates from U.S. tech majors Microsoft Inc., and Metal Platforms, and data showing a bigger than expected increase in euro zone inflation weighed on sentiment.
RTTNews
|
5h 41phút trước
